Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation

Molecular Endocrinology

Volumn 24, Issue 2, 2010, Pages 436-446

  Pöll, Florian ^a   Lehmann, Diana ^b   Illing, Susann ^a   Ginj, Mihaela ^d   Jacobs, Stefan ^c   Lupp, Amelie ^a   Stumm, Ralf ^a   Schulz, Stefan ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 3; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN 14; SOMATOSTATIN RECEPTOR 2; THREONINE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE; CELL STRAIN GH3; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOPLASM; DRUG RECEPTOR BINDING; ENDOSOME; HYPOPHYSIS ADENOMA; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, PHOSPHO-SPECIFIC; ARRESTINS; BETA-ADRENERGIC RECEPTOR KINASES; CELL LINE; CELL LINE, TUMOR; CELL MEMBRANE; ENDOCYTOSIS; HUMANS; LIGANDS; MALE; OCTREOTIDE; PANCREAS; PHOSPHORYLATION; PITUITARY GLAND; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RATS, WISTAR; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; THREONINE;

ANIMALIA; RATTUS;

EID: 75149175187     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2009-0315     Document Type: Article

References (42)

1. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C 2003 Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2:999-1017
2. Donangelo I, Melmed S 2005 Treatment of acromegaly: future. Endocrine 28:123-128
3. Oberg K 2005 Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment. Curr Opin Oncol 17:386-391
4. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, Schulz S, Boneu A, Guimbaud R, Buscail L 2008 Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 26:963-970
5. Plöckinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S, Schulz S 2008 Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab 93:1203-1210
6. Labeur M, Theodoropoulou M, Sievers C, Paez-Pereda M, Castillo V, Arzt E, Stalla GK 2006 New aspects in the diagnosis and treatment of Cushing disease. Front Horm Res 35:169-178
7. Silva AP, Schoeffter P, Weckbecker G, Bruns C, Schmid HA 2005 Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur J Endocrinol 153:R7-R10
8. van der Hoek J, Lamberts SW, Hofland LJ 2004 The role of somatostatin analogs in Cushing's disease. Pituitary 7:257-264
9. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716
10. Weckbecker G, Briner U, Lewis I, Bruns C 2002 SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 143:4123-4130
11. Lewis I, Bauer W, Albert R, Chandramouli N, Pless J, Weckbecker G, Bruns C 2003 A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem 46:2334-2344
12. Ma P, Wang Y, van der Hoek J, Nedelman J, Schran H, Tran LL, Lamberts SW 2005 Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther 78:69-80
13. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW 2005 The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152:645-654
14. Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW 2005 Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J Endocrinol Invest 28:36-42
15. Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ, Beckers A, Lamberts SW 2004 The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89:1577-1585
16. Murray RD, Kim K, Ren SG, Lewis I, Weckbecker G, Bruns C, Melmed S 2004 The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 89:3027-3032
17. Schmid HA 2008 Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001). Ann Endocrinol 69:162-163
18. Schmid HA, Schoeffter P 2004 Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 1(Suppl 80):47-50
19. Schmid HA, Silva AP 2005 Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats. J Endocrinol Invest 28:28-35
20. van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Poon KW, Lewis I, Weckbecker G, Krahnke T, Hofland LJ, Lamberts SW 2004 A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 89:638-645
21. van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ 2005 Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 289:E278-E287
22. Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S 2009 Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 94:654-661
23. Pfeiffer M, Koch T, Schröder H, Laugsch M, Höllt V, Schulz S 2002 Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 277:19762-19772
24. Tulipano G, Stumm R, Pfeiffer M, Kreienkamp HJ, Höllt V, Schulz S 2004 Differential β-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem 279:21374-21382
25. 2A somatostatin receptor. J Biol Chem 275:5591-5599
26. 2A somatostatin receptor phosphorylation. Mol Pharmacol 76:68-80
27. Fougner SL, Bollerslev J, Latif F, Hald JK, Lund T, Ramm-Pettersen J, Berg JP 2008 Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. J Clin Endocrinol Metab 93:1211-1216
28. Lorenz K, Lohse MJ, Quitterer U 2003 Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 426:574-579
29. de Bruin C, Feelders RA, Lamberts SW, Hofland LJ 2009 Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome. Rev Endocr Metab Disord 10:91-102
30. Schulz S, Mayer D, Pfeiffer M, Stumm R, Koch T, Höllt V 2004 Morphine induces terminal micro-opioid receptor desensitization by sustained phosphorylation of serine-375. EMBO J 23:3282-3289
31. Zhang J, Ferguson SS, Barak LS, Bodduluri SR, Laporte SA, Law PY, Caron MG 1998 Role for G protein-coupled receptor kinase in agonist-specific regulation of μ-opioid receptor responsiveness. Proc Natl Acad Sci USA 95:7157-7162
32. Kohout TA, Nicholas SL, Perry SJ, Reinhart G, Junger S, Struthers RS 2004 Differential desensitization, receptor phosphorylation, β-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem 279:23214-23222
33. Zidar DA, Violin JD, Whalen EJ, Lefkowitz RJ 2009 Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci USA 106:9649-9654
34. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG 2001 Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-β-arrestin complexes after receptor endocytosis*. J Biol Chem 276:19452-19460
35. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS 2000 Differential affinities of visual arrestin, β arrestin1, and β arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 275:17201-17210
36. Ahn S, Shenoy SK, Wei H, Lefkowitz RJ 2004 Differential kinetic and spatial patterns of β-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem 279:35518-35525
37. Lefkowitz RJ, Shenoy SK 2005 Transduction of receptor signals by β-arrestins. Science 308:512-517
38. Fischer T, Doll C, Jacobs S, Kolodziej A, Stumm R, Schulz S 2008 Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab 93:4519-4524
39. 2A). J Biol Chem 276:14027-14036
40. Mundschenk J, Unger N, Schulz S, Höllt V, Schulz S, Steinke R, Lehnert H 2003 Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 88:5150-5157
41. 2A. Clin Cancer Res 6:1865-1874
42. Ren XR, Reiter E, Ahn S, Kim J, Chen W, Lefkowitz RJ 2005 Different G protein-coupled receptor kinases govern G protein and β-arrestin-mediated signaling of V2 vasopressin receptor. Proc Natl Acad Sci USA 102:1448-1453